Showing results (2631-2640 of 2,835) with videos related to

Sort By:
Pageof 284
Nature Chemical Biology|October 26, 2023
Targeting ROS production through inhibition of NADPH oxidasesJoana Reis, Christoph Gorgulla, Marta Massari, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|September 9, 2023
Multi-organ phenotypes in mice lacking latent TGFβ binding protein 2 (LTBP2)Nicholas K Bodmer, Russell H Knutsen, Robyn A Roth, et al.
Molecular Medicine (Cambridge, Mass.)|July 27, 2001
Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapyA M Mhashilkar, R D Schrock, M Hindi, et al.
International Journal of Cancer|November 28, 2002
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancerShinichi Toyooka, Riichiroh Maruyama, Kiyomi O Toyooka, et al.
Clinical Lung Cancer|October 22, 2018
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC)Yasir Y Elamin, Daniel R Gomez, Mara B Antonoff, et al.
JCI Insight|December 8, 2022
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndromeXavier Mariette, Francesca Barone, Chiara Baldini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and NeckJohn Nemunaitis, Gary Clayman, Sanjiv S Agarwala, et al.
Cancer Research|May 17, 2008
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphomaValeria R Fantin, Andrey Loboda, Cloud P Paweletz, et al.
Cancer Research|December 4, 2002
BRAF and RAS mutations in human lung cancer and melanomaMarcia S Brose, Patricia Volpe, Michael Feldman, et al.
American Journal of Cancer Research|January 8, 2021
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutationsXiaoshan Zhang, Ran Zhang, Huiqin Chen, et al.
Pageof 284